Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Liver Damage in Hepatitis C Patients Could be Treated with Warfarin

Published: Friday, August 01, 2008
Last Updated: Friday, August 01, 2008
Bookmark and Share
The drug warfarin may help prevent liver failure in thousands of people with Hepatitis C, according to new research.

In a study published in the Journal of Thrombosis and Haemostasis, researchers show that warfarin reduces the scarring on the liver caused by Hepatitis C. This scarring, or fibrosis, replaces normal liver cells and can lead to cirrhosis of the liver and ultimately liver failure.

Following the new findings in mouse models, the Imperial College London researchers are now embarking on a clinical trial of warfarin as a treatment for people with Hepatitis C, funded by the Medical Research Council (MRC).

There are an estimated 300,000 people in the UK with chronic Hepatitis C. The disease progresses much more quickly in some patients than in others and around one in five of those infected will develop cirrhosis.

Treatment to clear the infection is currently effective in only around 50 percent of patients and can have considerable unpleasant side effects such as fatigue, nausea and depression. If this treatment fails, there are no currently effective therapies to slow the progression of fibrosis.

The new research looks at how warfarin affects the progression of fibrosis in mice with chronic liver injury. Warfarin is already used to prevent and treat blood clots in people with artificial heart valves, deep vein thrombosis, and a host of other conditions.

A previous study by the same researchers demonstrated that in Hepatitis C, scarring of the liver accelerates in those patients who are prone to form blood clots. This led the researchers to believe that warfarin's anti-clotting properties might enable the drug to fight the disease.

The new study showed that treatment with warfarin significantly reduces the progression of fibrosis in normal mice with chronic liver injury. It also shows that warfarin reduces the progression of fibrosis in mice with chronic liver injury and a genetic mutation known as Factor V Leiden (FVL), which causes fibrosis to progress at a much faster rate than usual because it amplifies the body's clotting mechanisms.

Professor Mark Thursz, one of the authors of the study from the Division of Medicine at Imperial College London, said: "At the moment there are a great many people with Hepatitis C who have no treatment options left and it would transform their lives if we could prevent them from developing liver failure.  We are looking forward to seeing the results of our upcoming trial in humans now that we've had such promising results in the trial in mice."

Dr Quentin Anstee, an MRC Clinical Research Fellow and the corresponding author of the study from Imperial College London, added: "If we have positive results from the new trial, we will have a potential treatment that is already available and very cheap, and which should be safe enough for people to take. If we are successful in Hepatitis C patients, we are hopeful that such treatment might benefit people with liver damage from other causes, and this is something we would be keen to study further."

The researchers are recruiting 90 patients for the new trial who have undergone a liver transplant as a result of liver failure caused by hepatitis C. A third of such patients progress very rapidly to fibrosis following transplantation.

The researchers hope that treating these patients with warfarin will prevent this liver damage and improve their prognosis. Transplant patients have a liver biopsy every year following transplantation to assess their progress, and the researchers will analyze data from this biopsy to establish the effectiveness of the warfarin treatment.

The two-year trial will take place across five centres including Imperial College Healthcare NHS Trust, which has integrated with Imperial College London to form the UK's first Academic Health Science Centre.

The trial is taking place in transplant patients because the researchers estimate that it would take 10-15 years to conduct a trial in patients in whom the disease was progressing at a normal rate.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

New Technique Negotiates Neuron Jungle To Target Source Of Parkinson’s Disease
Researchers from Imperial College London and Newcastle University believe they have found a potential new way to target cells of the brain affected by Parkinson’s disease.
Wednesday, September 23, 2015
Using Human Stem Cells To Identify Dangerous Side Effects Of Drugs
Scientists have developed a test that uses cells from a single donor's blood to predict whether a new drug will cause a severe reaction in humans.
Monday, March 09, 2015
Switch that Enables Salmonella to Sabotage Host Cells Revealed in new Study
A new switch that enables Salmonella bacteria to sabotage host cells is revealed in a study published in the journal Science.
Friday, April 23, 2010
Research Reveals Exactly How Coughing is Triggered by Environmental Irritants
Scientists identify the reaction inside the lungs that can trigger coughing when a person is exposed to particular irritants in the air.
Monday, November 23, 2009
Drug Shrinks Lung Cancer Tumours in Mice
A potential new drug for lung cancer has eliminated tumours in 50% of mice in a new study published today in the journal Cancer Research.
Monday, November 09, 2009
Scientists Discover new Genetic Variation that Contributes to Diabetes
Study identifies a genetic variation in people with type 2 diabetes that affects how the body's muscle cells respond to the hormone insulin.
Tuesday, September 08, 2009
Urine Samples could be Used to Predict Responses to Drugs, Say Researchers
Researchers show possibility to predict how different individuals would deal with one drug by looking at metabolites in their urine.
Tuesday, August 11, 2009
Schizophrenia Linked to Signaling Problems in New Brain Study
The study supports the theory that abnormalities in the way in which cells 'talk' to each other are involved in the disease.
Wednesday, March 04, 2009
Alzheimer's Disease Patients Show Improvement in Trial of new Drug
A new drug has been shown to improve the brain function of Alzheimer's patients and reduce a key protein associated with the disease in the spinal fluid.
Wednesday, July 30, 2008
Gene Sequence that can make Half of us Fatter is Discovered
Researchers have found a gene sequence linked to an expanding waist line, weight gain and a tendency to develop type 2 diabetes.
Monday, May 05, 2008
Chemical Signature of Manic Depression Discovered by Scientists
People with manic depression have a distinct chemical signature in their brains, according to a new study.
Thursday, February 07, 2008
Targeting Gut Bugs could Revolutionize Future Drugs, say Researchers
Revolutionary new ways to tackle certain diseases could be provided by creating drugs which change the bugs in people's guts.
Monday, February 04, 2008
Research Showing How Drugs Stick to a Key Protein
This information should help scientists to modify the structures of drugs to improve their effectiveness.
Monday, October 17, 2005
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Personalized Drug Screening for Multiple Myeloma Patients
A personalized method for testing the effectiveness of drugs that treat multiple myeloma may predict quickly and more accurately the best treatments for individual patients with the bone marrow cancer.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
Cancer-Fighting Tomato Component Traced
The metabolic pathway associated with lycopene, the bioactive red pigment found in tomatoes, has been traced by researchers at the University of Illinois.
Batten Disease may Benefit from Gene Therapy
NIH-funded animal study suggests one-shot approach to injecting genes.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.
Molecule Proves Key to Brain Repair After Stroke
Scientists found that a molecule known as growth and differentiation factor 10 (GDF10) plays a key role in repair mechanisms following stroke.
Towards Patient-Specific Drug Screening
A new breakthrough by the 3D stem cell printing team at Heriot-Watt could pave the way to individually tailored drug testing regimes, both reducing the need for animal testing and ensuring that patients receive drugs which are most effective for their individual needs.
Antibody Targets Key Cancer Marker
University of Wisconsin-Madison researchers have created a molecular structure that attaches to a molecule on highly aggressive brain cancer and causes tumors to light up in a scanning machine.
Gut Bacteria Can Dramatically Amplify Cancer Immunotherapy
Manipulating microbes maximizes tumor immunity in mice.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos